India’s Marksans Pharma is seeking approval from its shareholders to divest or lease out its two active pharmaceutical ingredient (API) …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

